Sanuwave Health, Inc. SNWV

Despite a 13% surge in recurring applicator revenue, the company faces headwinds from a 34% drop in system sales and proposed CMS reimbursement cuts, leading to a withdrawal of FY2026 guidance.

Moby summary of SANUWAVE Health, Inc.'s Q2 2026 earnings call

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025. EDEN PRAIRIE, Minn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-cleared wound care products, is pleased to provide its financial results for the three months ended June 30, 20

EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, August 7, 2026, at 8:30 AM (ET) to present its Q2 2026 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-274-8461Toll/International: 1-203-518-9814Conference ID:

Sanuwave announces preliminary, unaudited revenues of $9.6 million to $9.8 million for the second quarter ended June 30, 2026, above the high end of the Company’s revised guidance of $8.5 to $9.5 millionEDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the

Sanuwave Health's (SNWV) Q2 revenue is expected to be in the range of $8.5 million to $9.5 million,

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, b

SANUWAVE Health Inc (SNWV) reports its highest Q1 revenue ever, despite facing pricing challenges and increased operating expenses.

SANUWAVE Health Inc (OTC:SNWV) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d7338d6 Summary SANUWAVE Health Inc reported record Q1 revenues of $9.6 million, a 3% in

Moby summary of SANUWAVE Health, Inc.'s Q1 2026 earnings call

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025. Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025 EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Com

The updated analyst work keeps SANUWAVE Health's fair value price target at US$43.50, with no change to the target level itself. Supportive analysts argue that this steady target still points to room for value creation if the company delivers on commercialization and capital allocation plans, while more cautious voices highlight execution and discount rate risks around that same figure. As you read on, you will see how these differing views shape the evolving narrative around SANUWAVE...